Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of INCB123667 vs Chemotherapy in Platinum-Resistant Ovarian Cancer with Cyclin E1 Overexpression
jRCT2021250042Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of INCB123667 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Incyte. Primary endpoints: Progression-Free Survival (PFS) by BICR and Overall Survival (OS). Started Mar 2026; status: recruiting.
02
Drugs
INCB123667
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2021250042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250042.